

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Elixinol Wellness Limited</b>
<b>ABN</b>	<b>34 621 479 794</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Fenlon
<b>Date of last notice</b>	12 December 2024

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	20 December 2024
<b>No. of securities held prior to change</b>	625,294 fully paid ordinary shares 996,307 performance rights 78,125 unlisted options exercisable at \$0.16 per option, expiring 31 August 2025 78,125 unlisted options exercisable at \$0.16 per option, expiring 23 November 2025
<b>Class</b>	(a) Fully paid ordinary shares (b) Performance rights
<b>Number acquired</b>	(a) 938,087 (b) Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	(a) Nil (b) 938,087
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) Director Fee Rights issued in lieu of cash consideration with a deemed issue price of \$0.04264 per Director Fee Right (b) Nil cash consideration paid on vesting of Director Fee Right
<b>No. of securities held after change</b>	1,563,381 fully paid ordinary shares 58,220 performance rights 78,125 unlisted options exercisable at \$0.16 per option, expiring 31 August 2025 78,125 unlisted options exercisable at \$0.16 per option, expiring 23 November 2025
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of fully paid ordinary shares upon vesting of a portion of Director Fee Rights as approved by Shareholders at the Company's Annual General Meeting held on 30 May 2024

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.